Also, in a study conducted on 48 patients with advanced melanoma, 35 patients received anti-PD-1 monotherapy, 11 received anti-PD-1 and anti-CTLA-4, and 2 received anti-CTLA-4 monotherapy [88]. This evidence concerns the gene PDCD1 and melanoma.